Overall, our results prove that different NPM1 mutations mediate diverse clinical-biological characteristics of AML cells, suggesting that patients with AML harboring a NPM1 mutation may benefit from a refined sub-classification (A-like or non-A-like-mutated) and a subsequent tailored management including the possibility of novel target treatment strategies to improve their outcome. This evidence concerns the gene NPM1 and acute myeloid leukemia.